manilatimes

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional ...

"This is a historic moment for our company and for the patients we serve, as we fulfill our promise to translate our science into medicines that may make a meaningful difference in patients’ lives,” ...
clinicaladvisor.com

Virtual Reality Tool Assesses Functional Capacity in Early Schizophrenia

man with virtual reality goggles on Researchers found data that showed young patients in the early phase of schizophrenia would benefit by the Virtual Reality Functional Capacity Assessment Tool, as a ...
BMJ

Optimal dose and type of physical activity to improve functional capacity and minimise adverse events in acutely hospitalised older adults: a systematic review with dose ...

Objective To identify the optimal dose and type of physical activity to improve functional capacity and reduce adverse events in acutely hospitalised older adults. Design Systematic review and ...
Seeking Alpha

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional ...

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (CYTK) today announced that the U.S. Food and Drug Administration (FDA) has approved MYQORZO™ (aficamten), 5 ...
Mena FN

Cytokinetics Announces FDA Approval Of MYQORZOTM (Aficamten) For The Treatment Of Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy To Improve Functional Capacity ...

Company to Host Investor Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the ...